CWM
MREO

Cranbrook Wealth Management’s Mereo BioPharma MREO Stock Holding History

Cranbrook Wealth Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-60
Closed -$210 – 447
2024
Q4 		$210 Hold
60
– – ﹤0.01% 396
2024
Q3 		$247 Buy
+60
New +$248 ﹤0.01% 361

Other funds holding MREO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Cranbrook Wealth Management's MREO Position: Q1 2025 in Review

Cranbrook Wealth Management sold out of Mereo BioPharma (MREO) in Q1 2025, closing a stake of 60 shares — an estimated $210 sold.

Cranbrook Wealth Management first reported a position in MREO in Q3 2024 and held it in 2 quarters. The position peaked at $247 in Q3 2024. 90 funds tracked by Wall St. Rank hold MREO as of Q1 2025.

  • Cranbrook Wealth Management reported no remaining Mereo BioPharma position as of Q1 2025 after selling out during the quarter.
  • Cranbrook Wealth Management sold 60 Mereo BioPharma shares in Q1 2025, an estimated $210.
  • Cranbrook Wealth Management first reported a position in Mereo BioPharma in Q3 2024 and held it in 2 quarters.
  • Cranbrook Wealth Management's Mereo BioPharma position peaked at $247 in Q3 2024.
  • 90 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2025.

Based on Cranbrook Wealth Management's 13F filing for Q1 2025, filed 11 Apr 2025.